Escalation of Opioid Withdrawal Frequency and Subsequent AMA Rates in Hospitalized Patients From 2017 to 2020

Journal of Addiction Medicine: June 09, 2022

Objective: 

To measure trends for the emergence of opioid withdrawal (OW) and leaving against medical advice (AMA) among hospitalized patients.

Method: 

Retrospective time-series of hospitalized patients with OW, defined by a Clinical Opioid Withdrawal score ≥8, using electronic health record data at a tertiary health system and of patients with a discharge status of AMA from January 1, 2017 to December 31, 2020.

Results: 

The average number of monthly hospitalizations with OW showed a year-to-year increment of 15% in 2018, 21% in 2019, and 34% from 2019 to 2020, whereas the total monthly hospitalizations remained stable. The segmented regression analysis showed that the upward trend in hospitalizations with OW became significant after January 2019 (slope: 1.14, 95% confidence interval [CI]: 0.70, 1.57). After August 2019, Fentanyl was added to the hospital urine drug testing panel and was identified in most OW patients. The monthly proportion of patients who left AMA was significantly higher among the OW patients than among all other admitted patients. There was a significant increase of 0.39 (95% CI: 0.29–0.49, P ≤ 0.001) per month in %AMA among patients with OW. The estimated difference in %AMA among OW patients versus all other patients was 7.25 (95% CI: 5.12–9.38) in January 2017, and 16.92 (95% CI: 14.6019.24) in December 2020.

Conclusions: 

The number of hospitalized patients either presenting with or developing OW increased between 2017 and 2020 with a significant rise occurring after January 2019. The percentage of patients who left AMA among those who developed OW steadily worsened during the entire study period.


Popular posts from this blog

Managing Patients Taking Xylazine-Adulterated Opioids in Emergency, Hospital, and Addiction Care Settings

Wednesday, June 14, 2023 .   In response to the rapid escalation in the detection of xylazine in the unregulated drug supply, in April 2023, the White House designated fentanyl contaminated with xylazine an "emerging threat". The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) convened health care professionals and federal partners to review current practices in xylazine-related testing, treatment, and wound care to inform evolving best-practices in the field. This convening focused on the most critical areas of concern with the goal of rapidly identifying current practices and a xylazine-opioid research agenda.   https://nida.nih.gov/news-events/meetings-events/2023/06/managing-patients-taking-xylazine-adulterated-opioids-emergency-hospital-addiction-care-settings
Read more

Prescription Drug Misuse and Addiction: Compassionate Care for a Complex Problem

This CME activity provides a practical approach to the management of prescription drug misuse and addiction, including how to use the clinical interview and CURES (California's Prescription Drug Monitoring Program) to identify if a problem exists, and how to intervene once the problem has been identified. Animated didactic videos, interactive slides, and video case scenarios will be used to put these principles into practice with a treatment algorithm. The most compassionate approach to tapering patients down and off the medication they are misusing will also be discussed.   https://edhub.ama-assn.org/stanford-medicine-cme/provider-referrer/14533
Read more

International Overdose Awareness Day, August 31

https://www.cdc.gov/drugoverdose/awareness/ioad.html August 31 marks  International Overdose Awareness Day   (IOAD) , the world’s largest annual campaign to end overdose. It’s a day to: Remember  loved ones who have died from drug overdose and acknowledge the grief of the family and friends left behind. Take action  to encourage support and recovery for everyone impacted by substance use and overdose. End overdose  by spreading awareness of overdose prevention strategies. Hashtags : #IOAD2023 #EndOverdose
Read more